These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 28965421)
1. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421 [TBL] [Abstract][Full Text] [Related]
2. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Capdevila J; Carrato A; Tabernero J; Grande E Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525 [TBL] [Abstract][Full Text] [Related]
3. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Van Cutsem E; Yoshino T; Hocke J; Oum'Hamed Z; Studeny M; Tabernero J Clin Colorectal Cancer; 2016 Mar; 15(1):91-94.e1. PubMed ID: 26603056 [TBL] [Abstract][Full Text] [Related]
4. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology. Dhillon S Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578 [TBL] [Abstract][Full Text] [Related]
6. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Van Cutsem E; Yoshino T; Lenz HJ; Lonardi S; Falcone A; Limón ML; Saunders M; Sobrero A; Park YS; Ferreiro R; Hong YS; Tomasek J; Taniguchi H; Ciardiello F; Stoehr J; Oum'Hamed Z; Vlassak S; Studeny M; Argiles G Ann Oncol; 2018 Sep; 29(9):1955-1963. PubMed ID: 30010751 [TBL] [Abstract][Full Text] [Related]
7. The potential role of nintedanib in treating colorectal cancer. Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871 [TBL] [Abstract][Full Text] [Related]
8. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer. Noonan S; Man Wong K; Jimeno A Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849 [TBL] [Abstract][Full Text] [Related]
9. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Lee YC; Michael M; Zalcberg JR Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373 [TBL] [Abstract][Full Text] [Related]
10. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. Török S; Cserepes T M; Rényi-Vámos F; Döme B Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829 [TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874 [TBL] [Abstract][Full Text] [Related]
13. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Reck M Expert Rev Anticancer Ther; 2015 May; 15(5):579-94. PubMed ID: 25831142 [TBL] [Abstract][Full Text] [Related]
14. Nintedanib for the treatment of non-small-cell lung cancer. Rashdan S; Hanna N Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846 [TBL] [Abstract][Full Text] [Related]
15. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737 [TBL] [Abstract][Full Text] [Related]
16. Nintedanib in non-small cell lung cancer: from preclinical to approval. Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060 [TBL] [Abstract][Full Text] [Related]
17. Nintedanib: from discovery to the clinic. Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Mitchell EP Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896 [TBL] [Abstract][Full Text] [Related]
19. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097 [TBL] [Abstract][Full Text] [Related]
20. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]